

PROLASTIN®-C LIQUID: #1 prescribed in alpha-1

THE NEXT WAVE
IN ALPHA-1
THERAPY

25
YEARS

The #1 prescribed alpha-1 therapy every year for more than 25 years—now in a ready-to-infuse, liquid formulation^{1,2}



Experience of over 4 million infusions worldwide³



>90% success rate in obtaining coverage and the Assist \$0 copay program providing up to \$6600/year for eligible patients⁴



One dedicated coordinator specifically assigned to support you and your patients for a seamless transition⁴



Automatic enrollment in an alpha-1 disease-management program proven to impact compliance and healthcare utilization^{4,5}

Important Safety Information

PROLASTIN®-C LIQUID is an alpha₁-proteinase inhibitor (human) (alpha₁-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha₁-PI (alpha₁-antitrypsin deficiency).


Limitations of Use

- The effect of augmentation therapy with any alpha₁-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha₁-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials

Please see Important Safety Information continued on reverse side and refer to accompanying full Prescribing Information for PROLASTIN-C LIQUID.

References: 1. Barker A, Campos M, Brantly M, et al. Bioequivalence of a liquid formulation of alpha₁-proteinase inhibitor compared with Prolastin®-C (lyophilized alpha₁-PI) in alpha₁-antitrypsin deficiency. *COPD*. 2017;14(6): 590-596. 2. Data on file, Executive Summary, Grifols. 3. Data on file, Grifols. 4. Data on file, PROLASTIN DIRECT program, Grifols. 5. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. *COPD*. 2009;6(1):31-40.

GRIFOLS



#1

PRESCRIBED
IN
ALPHA-1

Just 1 step gets your patients started

Complete the enclosed enrollment form to start new patients on or transition existing patients to PROLASTIN-C LIQUID today.

Important Safety Information (cont'd)

Limitations of Use (cont'd)


- Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
- PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha₁-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha₁-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).



GRIFOLS

Please see accompanying full Prescribing Information for PROLASTIN-C LIQUID.

© 2018 Grifols All rights reserved
April 2018 BN/PRL/0218/0004